| Relaxin: a new approach for the treatment of acute congestive heart failure. | |
| | |
MedLine Citation:
|
PMID: 20926940 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Relaxin, a naturally-occurring hormone in the insulin family, was discovered to have a physiologic role in pregnancy. Named initially for its relaxing effect on the pubic ligament, relaxin receptors have since been found to be widely distributed in many organs in both males and females. Acting through multiple pathways, including the stimulation of gelatinases leading to activation of endothelin type B receptors and subsequently nitric oxide, relaxin has been shown to cause vasodilation. In animal models and studies in humans, relaxin has been shown to increase cardiac output and renal perfusion. Due to these effects, relaxin has been examined as a treatment for acute heart failure. The results of phase I and II trials have shown favorable clinical trends without any major adverse events, suggesting that relaxin has the potential to be an effective medication for acute heart failure in conjunction with or in place of current treatments. |
| | |
Authors:
|
Jason Grossman; William H Frishman |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cardiology in review Volume: 18 ISSN: 1538-4683 ISO Abbreviation: Cardiol Rev Publication Date: 2010 Nov-Dec |
Date Detail:
|
Created Date: 2010-10-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9304686 Medline TA: Cardiol Rev Country: United States |
Other Details:
|
Languages: eng Pagination: 305-12 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular di...
Next Document: Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.